Compugen(NASDAQ) CGEN

Market Cap$249.13M

Since IPO (2000)-76%

5 Year-62%

1 Year+84%

1 Month+11%

Premium Feature

Moneyball Superscore

73/100

$2.63

+1.54%

+0.04Today

Compugen last closing stock price
Metric	Price	Date
Last close	USD 2.63	2026-09-02

Compugen stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-7.39%	USD 2.84	2026-08-26
1 month	+10.5%	USD 2.38	2026-08-03
3 month	+18.47%	USD 2.22	2026-06-04
Year to date	+71.9%	USD 1.53	2025-12-31
1 year	+83.92%	USD 1.43	2025-09-02
3 year	+130.7%	USD 1.14	2023-09-01
5 year	-62.16%	USD 6.95	2021-09-03
Since inception	-76.36%	USD 11.13	2000-08-11

Compugen Financials at a Glance

Market Cap

$249.13M

Revenue (TTM)

$74.00M

Net Income (TTM)

$35.19M

EPS (TTM)

$0.37

P/E Ratio

7.10

Dividend

$0.00

Beta (Volatility)

1.65 (High)

Dividend

$0.00

Beta (Volatility)

1.65 (High)

Price

$2.63

Volume

318

Open

$2.56

Price

$2.63

Volume

318

Open

$2.56

Previous Close

$2.63

Daily Range

$2.56 - $2.63

52-Week Range

$1.30 - $3.24

Estimated Earnings Date

Nov 9, 2026

Dividend

$0.00

Beta (Volatility)

1.65 (High)

Price

$2.63

Volume

318

Open

$2.56

Previous Close

$2.63

Daily Range

$2.56 - $2.63

52-Week Range

$1.30 - $3.24

Estimated Earnings Date

Nov 9, 2026

CGEN News

Page 1

CGEN: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Compugen

Compugen Ltd. is a clinical-stage biotechnology company based in Israel, focused on the discovery and development of innovative therapeutic candidates. Established in 1993, the company operates in the fields of immuno-oncology, with a robust pipeline of investigational treatments aimed at addressing various solid tumors.

Products and Services

COM701: An anti-PVRIG antibody in Phase I clinical trials for solid tumors
COM902: A therapeutic antibody targeting TIGIT, also in Phase I trials
Bapotulimab: An antibody targeting ILDR2, currently in Phase I development

Growth Outlook

Strong pipeline with multiple candidates in clinical trials, enhancing future revenue potential
Strategic partnerships with major pharmaceutical companies like Bayer and Bristol-Myers Squibb
Focus on myeloid targets may lead to innovative treatment options in immuno-oncology

Financial Highlights

Recent quarterly revenue of $2.6 million, showing growth from previous quarters
Trailing twelve months (TTM) net profit margin of 47.55%, indicating operational efficiency
Current ratio of 5.72, reflecting strong liquidity position

Compugen Ltd. is positioned in a promising sector with a focus on immuno-oncology, which is gaining traction in the healthcare industry. The company's strategic collaborations with leading pharmaceutical firms enhance its research capabilities and market reach. The ongoing clinical trials for its innovative therapies could potentially lead to significant advancements in cancer treatment, making it a noteworthy player in the biotechnology landscape. Recent financial performance indicates a solid foundation, with a strong liquidity position and operational efficiency, which may attract investor interest as the company continues to develop its pipeline.

AI Generated • Aug 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Eran Ophir, PhD

Website

www.cgen.com

Headquarters

Holon, TA 5885849, IL

CGEN Financials

Key Financial Metrics (TTM)

Gross Margin

86.89%

Operating Margin

40.94%

Net Income Margin

47.55%

Return on Equity

42.57%

Return on Capital

29.64%

Return on Assets

25.43%

Earnings Yield

14.08%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$249.13M

Shares Outstanding

94.73M

Volume

318

Avg. Volume

308.68K

Financials (TTM)

Gross Profit

$64.30M

Operating Income

$30.30M

EBITDA

$35.24M

Operating Cash Flow

$0.00

Capital Expenditure

$0.00

Free Cash Flow

$0.00

Cash & ST Invst.

$125.30M

Total Debt

$3.02M

Compugen Performance Analysis

Compugen annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 7,500,000	25.0%
2023	2023-12-31	USD 33,459,000	346.1%
2024	2024-12-31	USD 27,864,000	-16.7%
2025	2025-12-31	USD 72,764,000	161.1%

Compugen sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	50.4%
Q4	2025-12-31	3460.7%
Q1	2026-03-31	-96.8%
Q2	2026-06-30	19.6%

Compugen annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.39	-4.2%
2023	2023-12-31	USD -0.21	-45.0%
2024	2024-12-31	USD -0.16	-25.7%
2025	2025-12-31	USD 0.38	N/A

Compugen sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	5.0%
Q4	2025-12-31	904.3%
Q1	2026-03-31	-113.3%
Q2	2026-06-30	12.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$2.60M

+107.0%

Gross Profit

-$92.00K

+77.5%

Gross Margin

-3.54%

N/A

Market Cap

$249.13M

N/A

Market Cap/Employee

$3.32M

N/A

Employees

N/A

Net Income

-$7.01M

+4.6%

EBITDA

-$7.00M

+4.9%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$125.30M

+33.5%

Total Debt

$3.02M

+1.8%

Accounts Receivable

$4.11M

+9.1%

Inventory

$0.00

N/A

Long Term Debt

$2.40M

-4.0%

Short Term Debt

$623.00K

+32.3%

Return on Assets

25.43%

N/A

Return on Invested Capital

26.18%

N/A

Free Cash Flow

$0.00

N/A

Operating Cash Flow

$0.00

N/A

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

TNXPTonix Pharmaceuticals Holding Corp.

TNXPTonix Pharmaceuticals Holding Corp.$13.56+1.31%

CRBPCorbus Pharmaceuticals Holdings, Inc.

CRBPCorbus Pharmaceuticals Holdings, Inc.$11.38-0.85%

IPHAInnate Pharma S.A.

IPHAInnate Pharma S.A.$2.11-2.82%

MOLNMolecular Partners AG

MOLNMolecular Partners AG$4.30+5.65%

MISTMilestone Pharmaceuticals Inc.

MISTMilestone Pharmaceuticals Inc.$1.25+5.93%

CRDFCardiff Oncology, Inc.

CRDFCardiff Oncology, Inc.$1.07+0.94%

RANIRani Therapeutics Holdings, Inc.

RANIRani Therapeutics Holdings, Inc.$0.87+1.28%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares

KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares$20.15+0.05%

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$51.83-0.01%

BIAFbioAffinity Technologies

BIAFbioAffinity Technologies$9.75+0.48%

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$106.35+0.00%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$69.60+0.01%

TVATexas Ventures Acquisition III Corp

TVATexas Ventures Acquisition III Corp$10.55+0.00%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.37+0.00%

Questions About CGEN

What is the current price of Compugen?

Compugen is trading at $2.63 per share.

What is the 52-week range for Compugen?

Over the past 52 weeks, Compugen has traded between $1.30 and $3.24.

How much debt does Compugen have?

As of the most recent reporting period, Compugen reported total debt of $3.02M.

How much cash does Compugen have on hand?

Compugen reported $10.28M in cash and cash equivalents in its most recent financial results.

What is Compugen’s dividend yield?

Compugen does not currently have a dividend yield.

Compugen(NASDAQ) CGEN

Compugen Financials at a Glance

CGEN News

Why Compugen Shares Are Up Today

Why Compugen Stock Got Slammed Today

Why Shares of Compugen Rose on Thursday

Why Shares of Compugen Rose 16.5% on Wednesday

Why Shares of Compugen Jumped 17.86% on Thursday

Why Compugen Stock Crumbled Today

Why Shares of Compugen Jumped 9.27% on Tuesday

Why Compugen Stock Got Slammed Today

CGEN: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Compugen

CGEN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Compugen Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CGEN

What is the current price of Compugen?

What is the 52-week range for Compugen?

How much debt does Compugen have?

How much cash does Compugen have on hand?

What is Compugen’s dividend yield?

Premium Investing Services